glp 1 and GLP-1 medications get at the heart of addiction: study – WashU Medicine Current Insights, Advantages and Challenges

Shimada et al

For patients comparing options in the GLP-1 family, our tirzepatide 3-month weight loss guide can help set realistic expectations about progress over time

Medicare GLP-1 Bridge program Beginning July 1, 2026 through December 31, 2027, eligible Medicare beneficiaries can access the following FDA-approved GLP-1 medications for weight loss : Wegovy (injection or tablet), Foundayo (tablet), and Zepbound (KwikPen only) for $50/month *** through the Medicare GLP-1 Bridge program

Furthermore, the Outsourcing Facilities Association has sued the FDA, claiming the removal of semaglutide from the shortage list is arbitrary and capricious because there are still risks of supply shortages